Recently Featured

ViiV Healthcare advances paediatric HIV regulatory submissions with FDA Priority Review for Tivicay PD and EMA validation of marketing application for Tivicay

June 29, 2026
London – ViiV Healthcare, the global specialist HIV company majority owned by GSK, announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) to extend the use of Tivicay PD (dolutegravir (DTG)) to newborns from birth. The FDA has granted Priority Review for this application, with a Prescription…

Brain-Infiltrating T Cells Linked to Social Deficits in Autism Mouse Model

June 28, 2026
The infiltration of γδ T cells in the brains of a genetic mouse model for autism spectrum disorder (ASD) has been linked to altered social behaviors, according to recent findings published in Science Immunology. This research highlights the potential role of immune dysregulation in the social deficits observed in ASD, a condition affecting approximately one…

Breast Milk Fatty Acid Shapes Immune Development in Mice

June 28, 2026
In a groundbreaking study published in Science, researchers from the University of Chicago have identified trans-vaccenic acid (TVA), the predominant trans fatty acid in human breast milk, as a significant factor in enhancing immune system development in mice. This discovery highlights the critical role that specific dietary components can play in shaping neonatal immune responses.…

Pharma Companies Accelerate Biotech Acquisitions Amid Resurgent M&A Activity

June 28, 2026
Pharmaceutical companies are actively engaging in a wave of biotech acquisitions, signaling a robust resurgence in mergers and acquisitions (M&A) within the sector. This trend reflects a strategic pivot as firms seek to enhance their portfolios with innovative therapies and technologies, particularly in the wake of promising clinical data. The current landscape is characterized by…

Ongoing Cases